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ABBREVIATIONS
AST Adeli suit treatment
CAM Complementary and alternative
medicine
MAST Modified Adeli suit therapy
NDT Neurodevelopmental treatment
PEDI Pediatric Evaluation of Disabil-
ity Inventory
PEDro Physiotherapy Evidence Data-
base
RCT Randomized control trial
AIM This systematic review and meta-analysis presents an overview of the efficacy of suit
therapy on functioning in children and adolescents with cerebral palsy (CP).
METHOD A systematic review with meta-analysis was conducted. A comprehensive search of
peer-reviewed articles was performed on electronic databases, from their inception to May
2014. Studies included were rated for methodological quality using the Physiotherapy
Evidence Database scale. Effects of suit therapy on functioning were assessed using meta-
analytic techniques.
RESULTS From the 46 identified studies, four met the inclusion criteria and were included in
the meta-analysis. Small, pooled effect sizes were found for gross motor function at post-
treatment (g=0.46, 95% confidence interval [CI] 0.10–0.82) and follow-up (g=0.47, 95% CI 0.03–
0.90).
INTERPRETATION The small number of studies, the variability between them, and the low
sample sizes are limitations of this review. Findings suggest that to weigh and balance
benefits against harms, clinicians, patients, and families need better evidence to examine and
prove the effects of short intensive treatment such as suit therapy on gross motor function in
children and adolescents with CP. Therefore, more research based on high-quality studies
focusing on functioning in all dimensions of the International Classification of Functioning,
Disability and Health perspective is necessary to clarify the impact of suit therapy.
Cerebral palsy (CP) designates a group of permanent dis-
orders of the development of movement and posture,
which causes activity limitations. These disorders are
attributed to non-progressive disturbances that occur in
the developing fetal or infant brain, and are often accom-
panied by other conditions such as: (1) disturbances of sen-
sation, perception, cognition, communication, and
behaviour; (2) epilepsy; and (3) secondary musculoskeletal
problems.1 In the general population, the estimated preva-
lence is two in every 1000 live births.2,3
From an International Classification of Functioning,
Disability and Health perspective (ICF), CP affects a per-
son’s ‘functioning’, inclusive of body structures and func-
tions, activities, and participation, which may in turn cause
‘disabilities’ such as impairments, activity limitations, and
participation restrictions.4 The limitations in activity
require individual rehabilitation throughout the lifespan.5
Rehabilitation in children with CP aims to minimize the
effect of physical impairments, promote independence, and
improve the quality of life of children and their families
who play a major role in the process.6,7 The process of
rehabilitation is influenced by the clinical type and severity
of the CP, the existence of additional disabilities (e.g.
visual, auditory, or cognitive), emotional problems, the
physiological age of the child, and the family’s socio-
economic status.8
The management of motor disability in CP includes
physical therapy and a wide spectrum of other thera-
peutic interventions.9 Physical therapy focuses on func-
tion, movement, and optimal use of the child’s
potential. Physical therapists use different therapeutic
approaches in the (re)habilitation of children with CP
to maintain and restore physical, psychological, and
social well-being.10,11
Context-focused therapy, bimanual training, constraint-
induced movement therapy, neurodevelopmental treatment
(NDT), goal-directed/functional training, muscle strength-
ening, and/or home programs for improving motor activi-
ties or self-care function are some of the therapeutic
approaches used in CP rehabilitation by physical therapists
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all around the world. However, no one treatment has been
shown to be conclusively effective at more than one level
of the ICF.12
In recent decades, different biomedical, surgical, and
biomechanical innovations have led to the development of
new intervention techniques11 in the (re)habilitation of
young people with CP, namely therapeutic garments with
a roughly similar construction and intention of Adeli suit13
such as dynamic movement orthoses or lycra body suit
orthoses.14 The designs of these orthoses range from full
body suits to smaller garments such as sleeves/gloves and
leggings.
Unfortunately, research studies evaluating the effects of
orthoses for people with CP often lack a well-specified
research question, sufficient detail of the methodology, and
adequate description of the participants and/or the inter-
vention. There is often a lack of clarity about what is being
evaluated in orthotic research studies.15
The original suit was developed for Russian cosmonauts
in the late 1960s. It was referred to as a ‘Penguin suit’ and
designed to counteract the adverse effects of zero gravity
including muscle atrophy and osteopenia, and maintain
neuromuscular fitness during weightlessness experienced by
cosmonauts. In 1991, the Adeli suit incorporated a proto-
type of a device developed in Russia for children with CP
and popularized by the EuroMed Rehabilitation Center in
Mielno, Poland.13,16
Since then, this dynamic orthotic has been popularized
in different countries and different designations have been
used according to their respective protocols (e.g. Adeli suit,
TheraSuit, and PediaSuit).17,18 The differences between
these protocols are not clear in the literature, and most
interventions use a combination of suits with intensive
physical therapy (i.e. 2–4h sessions, 5 or 6d/wk, over 3 or
4wks). Suit therapy is considered appropriate for children
from 2 years of age to adulthood.18,19
Adeli suit is a form-fitting garment with different attach-
ment points for straps and bungee cords that offer the
wearer support and resistance to movement.17 It consists
of a vest, shorts, kneepads, and specially connected shoes;
hooks, rings, and elastic bands connect the pieces of the
garment and are adjusted to optimally position limbs and
joints. Therapists attempt to correct the abnormal muscle
alignment by adjusting the bungee-like cords to mimic
normal flexor and extensor patterns of major muscle
groups. The elastic cords are assumed to create tension
thereby strengthening the muscles, and the deep pressure
at the joints is assumed to improve the sensory and propri-
oceptive information. The suit also aims to enhance the
vestibular system and improve coordination.16 The idea is
that once the body is in proper alignment, intensive move-
ment therapy can be performed that will re-educate the
brain to recognize correct movement of the muscles.13
The suit serves as a stability vest that produces a vertically
directed load of approximately 15 to 40 kg.20
This intervention protocol includes a rigorous physical
therapy protocol and treatment is based upon three princi-
ples: the effect of the suit (working against resistance loads,
increased proprioception, and realignment); 1 month of
intensive daily physical therapy; and active motor participa-
tion by the patient. Additionally, some protocols used ability
exercise units or functional cages. These cages can be used
in two ways: the ‘monkey cage’ uses a system of pulleys and
weights to isolate and strengthen specific muscles; and the
‘spider cage’ uses a belt and bungee cords to either assist
upright positioning or practice many other activities that
normally would require the support of more therapists.18
Some of the available literature advocates that suit therapy
has many benefits such as improving motor function and
posture,18 improving vertical stability (e.g. standing pos-
ture),21 increasing range of motion,22 normalizing electroen-
cephalography signals,23 providing proprioceptive input and
improving the vestibular system,15 improving symmetry,
increasing walking speed and cadence,24 improving trunk
control,25 motor function (in all dimensions of Gross Motor
Function Measure [GMFM]),26 and self-care27 capacity in
children with CP. However, most of these studies are case
reports or descriptive studies in which the methodological
quality limits the possibility of supporting or rejecting the
use of the suit therapy in clinical settings.21,28
A narrative review of the literature on the effects of suit
therapy,29 which included all of its applications in neuro-
logical dysfunctions as well as a wide range of study
designs (including case studies), concluded that the efficacy
of suit therapy has no sufficient evidence in the literature
on which to base clinical practice. In this review, the
authors highlighted the need for more research on the
effects of suit therapy in order to support evidence-based
interventions.
Families who have children with disabilities risk spend-
ing valuable resources on complementary and alternative
therapies that have not yet proven to be effective. Profes-
sionals should be cautious in encouraging families to pur-
sue these therapies when they are still in the early phases
of efficacy testing.30–32 However, the introduction of com-
plementary and alternative medicine (CAM) increases the
complexity of clinical reasoning required by clinicians.
Considering the current knowledge limitations regarding
the benefits of suit therapy, the aim of this systematic
review and meta-analysis was to examine the effects of suit
therapy on functioning in children and adolescents with
CP.
METHOD
This meta-analysis followed the Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA) state-
ment33 using a research question framed by the acronym
What this paper adds
• Suit therapy interventions have limited and heterogeneous effects on gross
motor function.
• Limitations of evidence on suit therapy should be considered when advising
parents.
• Provides a basis for future research studies on the implementation and
effectiveness of suit therapy in children and adolescents with CP.
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PICOS,34 which stands for Population (children and ado-
lescents with CP), Intervention (suit therapy), Comparator
(another therapeutic approach), Outcomes (functioning or
motor function), and Study design (randomized control tri-
als [RCTs]).
Search strategy
A comprehensive literature search was conducted in the
following electronic databases: Medline; CENTRAL
(Cochrane Central Register of Controlled Trials);
LILACS; OVIDSP; and PEDro (Physiotherapy Evidence
Database). According to the aim of this study, the search
expressions for Medline and CENTRAL were: ‘cerebral
palsy’ AND (‘motor function’ OR ‘functionality’ OR ‘func-
tioning’) AND (‘suit’ OR ‘pedia suit’ OR ‘thera suit’ OR
‘adeli suit’ OR ‘modified suit’ OR ‘neuro suit’ OR ‘pen-
guin suit’ OR ‘bungy suit’). The search expression was
adapted for the others databases (PEDro, LILACS, and
OVIDSP). Search strategies can be obtained from the
authors. The search dates covered the period from the
inception of the databases until 30 May 2014.
Inclusion criteria
Inclusion criteria were as follows: (1) RCTs reported in
peer-review journals; (2) languages: English, Portuguese,
Spanish and French; (3) studies investigating the effect of
suit therapy regardless of the type of protocol used (Pedia-
Suit, TheraSuit, NeuroSuit, Adeli suit, Penguin suit, or
Bungy suit); (4) studies conducted with samples that com-
prised children and adolescents (from 0–18y) with a clinical
diagnosis of CP regardless of the type and level of severity;
and (5) studies reporting functioning as the primary out-
come, assessed by means of standardized and internation-
ally accepted instruments (e.g. GMFM – 66 or 88 items,
and Pediatric Evaluation of Disability Inventory [PEDI]).
Exclusion criteria
Studies were excluded if: (1) the intervention used other
types of therapeutic garments that did not use elastic cords;
(2) participants had other diagnosed medical conditions
(e.g. neuromuscular diseases) or were aged over 18 years;
and (3) if the trial did not report at least one measure of
functioning assessed at baseline, post-treatment, and/or fol-
low-up.
Study selection
Relevant papers screened were entered into reference man-
agement software EndNote X7 (Thomson Reuters,
Philadelphia, PA, USA) and duplicate articles were
removed based on title and abstract matching. Studies were
selected if they fulfilled the inclusion criteria. Results were
conferred after each stage and the following stage would
only initiate when full consensus was reached.
Reviews, correspondences, and editorials were specifically
excluded, although their reference lists were hand-searched
to identify potentially relevant studies. Records were then
screened against the eligibility criteria before appraisal of
methodological quality. See Figure 1 for a flowchart illus-
trating the review process.
Data extraction
Five researchers independently read and extracted data
from all articles, and results were checked for accuracy
by the first author. Reviewers were not blind to author
(s), institution(s), or journals. Disagreements were
resolved by consensus between researchers. The follow-
ing information was retrieved from each study: author(s),
year of publication, type of study design, sample size,
instruments, intervention protocol, and outcomes. To
calculate effect sizes for selected outcomes, we extracted
sample sizes and baseline post-treatment, and follow-up
means and standard deviations. Outcome variable was
continuous. Authors of included trials were contacted
when necessary to retrieve missing data in published
studies.
Assessment of the methodological quality
Five reviewers independently rated the methodological
quality of included studies using the PEDro scale.35,36
During a consensus meeting, scoring disagreements were
resolved. Interrater agreement of quality assessment
between the five reviewers was assessed using two-way
mixed agreement and absolute agreement statistics, with a
confidence interval of 95%. The value of the intraclass cor-
relation coefficient was 0.99, indicating excellent agree-
ments.36
According to Foley et al.,37 studies scoring 9 to 10 on
the PEDro scale were considered to be of ‘excellent’
methodological quality, studies ranging from 6 to 8 were
rated as ‘good’ quality, studies scoring between 4 and 5
were considered to be of ‘fair’ quality, and studies scoring
below 4 were rated as ‘poor’ quality.
Statistical analysis
Data was synthesized using a fixed-effect model, because of
the limited number of studies (<5) available.38 Effect sizes
were the standardized mean difference with Hedge’s g cor-
rection39 for small samples, interpreted according to
Cohen’s40 guidelines (values of 0.20, 0.50, and 0.80 corre-
spond to small, medium, and large effects respectively),
and 95% confidence intervals were also derived for each
effect size. Z-values and corresponding p-values were con-
sidered as indicators of the significance of the pooled
effects. Two analyses were conducted, one for each mea-
surement point (baseline vs post-treatment, and baseline vs
follow-up). For the study by Mahani et al.,41 composite
effect sizes were computed as more than one intervention
arm (vs one control group) was included in the meta-ana-
lyses.
Analyses were inspected for heterogeneity using
Cochran’s Q statistic42 for which a significant p-value
(p<0.05) demonstrates that studies do not share a common
effect size, and I2 statistic43 which assesses the proportion
of observed dispersion that is caused by real differences in
Review 3
the true effect sizes. The I2 ranges from 0% to 100% (val-
ues of 25%, 50%, and 75% correspond to low, moderate,
and high heterogeneity).43 Publication bias was examined
by visual inspection for asymmetry of funnel plots and
Egger’s test44 to confirm the visual impression.
To confirm the validity of the results obtained, the
meta-analysis for the comparison between baseline and
post-treatment was repeated excluding the study by Alage-
san et al.,45 which had used a different version of the mea-
sure (GMFM-88).
Analyses were conducted using the Comprehensive
Meta-Analysis Software version 3 (Biostat, Englewod, NJ,
USA).46
RESULTS
Study selection
In the first stage, 46 potentially relevant articles were iden-
tified from the search strategy. After removing duplicates,
25 articles remained. After removing six articles which
were in Russian and screening the titles and abstracts of
potential studies, 11 full text articles were retrieved for full
reading. Seven of these articles were excluded for not
meeting inclusion criteria (not RCTs). Four studies were
eligible and included in the review for further analysis
(Fig. 1).
The four studies included in this review were published
between 2006 and 2011. Table I provides a descriptive
summary of these studies. In total, these studies included
110 participants. The mean number of participants in each
trial was 12.3 (SD 2.52) with a mean age of 6 years
11 months (SD 1y 10mo). Two RCTs compared Adeli suit
treatment (AST) with NDT:41,47 one study compared
modified suit therapy with conventional therapy,45 and the
other compared TheraSuit with a treatment categorized as
other therapy approach.48
Characteristics of included studies
The four RCTs presented variability regarding sample
characteristics (age, subtypes, and level of severity of CP),
instruments used to assess children and adolescent’s
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Figure 1: Flow chart of the article selection process. PEDro, Physiotherapy Evidence Database; CP, cerebral palsy; RCT, randomized controlled trial.
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Table I: Summary of identified studies
Study Selection criteria Sample
Variables/instru-
ments Intervention protocol Outcomes
Bar-Haim
et al.47
Inclusion criteria: diagnosis
of CP; 6–12y; GMFCS level
II, III, or IV; no orthopaedic
surgery or spasticity-
reduction intervention in
the previous 6mo; not a
candidate for surgery or
other interventions for at
least 1y; parents’
agreement for child
allocation to either group
by randomization.
Exclusion criteria: hip
dislocation or scoliosis;
high degree of spasticity;
poorly controlled epilepsy;
hydrocephalus and
progressive
encephalopathies and
myopathies
24 children
randomly
assigned to:
AST (n=12)
NDT (n=12)
Gross Motor
Function Measure
(GMFM-66);
metabolic cost of
stair climbing
(Mechanical
Efficiency Index)
AST in accordance with the
original Russian protocol.
NDT
Both groups were tested at
baseline and after 1mo of
AST or NDT therapy, and
again 9mo later after they
had returned to their
regular pre-study therapy.
Both groups received
daily treatment sessions
for about 2h, 5d/wk for
4wk (40h). During this
time they stopped routine
physiotherapy treatments,
but continued educational
and recreational activities
GMFM-66:
Significant time effect but
no group or interaction
effects.
AST – significant increase
between baseline and 1-
mo scores (p=0.037);
NDT – significant increase
between baseline and 10-
mo scores (p=0.006).
Mechanical Efficiency
Index:
Significant time effect but
no group or interaction
effects;
AST – significantly better at
10mo (p<0.05), greater
improvement in children
who had higher GMFM-66
scores at baseline.
NDT – no significant
change over time.
Alagesan
et al.45
Inclusion criteria: children
with spastic diplegic CP,
between 4 and 12y.
Exclusion criteria:
subluxation or dislocation
of hip, fracture of spine or
limbs, severe scoliosis,
seizures, intellectual
disability, severe spasticity
with contractures, and any
other congenital
deformity.
30 children
randomly
assigned
Conventional
therapy with
Modified
suit (EG)
(n=15)
Conventional
therapy (CG)
(n=15)
Gross Motor
Function Measure
(GMFM-88)
EG – conventional therapy
while wearing Modified
suit (vest, shorts, knee
pad, and shoe
attachments);
CG – conventional therapy.
Both groups were treated
for 2h daily with short
breaks of around 20min
for duration of 3wks (30h).
Both groups displayed
statistically significant
improvement (p<0.001).
In the post-treatment,
results were significantly
better in the EG than in
the CG (p=0.03).
Mahani
et al.41
Inclusion criteria: diagnosis
of CP; no orthopaedic
surgery or spasticity
reduction intervention in
the past 6mo; in GMFCS
level I, II, III, and IV; not a
candidate for surgery or
other intervention for at
least 1y; with parent’s
consent for child
assignment in either
group by randomization.
Exclusion criteria: hip
dislocation and marked
scoliosis; high degree of
spasticity and disability
(GMFCS level);
uncontrolled seizures;
hydrocephalous,
progressive
encephalopathies, and
myopathies; systemic
diseases such as renal or
cardiac disorders
36 children
assigned to
three
groups by
match pairs:
G1 – MAST
(n=12);
G2 – AST
(n=12);
G3 – NDT
Gross Motor
Function Measure
(GMFM-66)
All children in the three
groups received daily
treatment for 2h/d, 5d/wk
for a period of 4wks (40h).
AST group – 1h passive
intervention; 1h wearing
the Adeli suit practising
exercises for
strengthening the weak
musculatures and
optimizing the correct
posture and alignment.
NDT group – 1h of passive
intervention; 1h of
functional activities such
as sitting, standing up
from sitting, and walking.
MAST group – 1h of
passive intervention; 1h of
practice of functional and
goal-directed activities in
the context of play with
the suit.
After the treatment, all
children received
traditional occupational
therapy services for
16wks, twice a wk, and
45min/session.
No significant difference in
the GMF scores was
found among groups at
the baseline (p=0.965).
The MAST group had
significantly higher GMF
scores than the other two
groups after intervention
(4wks) (p<0.001) and
16wks after treatment
(p<0.001 between MAST
and AST; p=0.001
between MAST and NDT).
No differences were found
between the AST and
NDT groups at these
stages.
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functioning, and intervention protocols (duration, fre-
quency, intensity) (Table I).
Sample
Studies included children with CP at different severity
levels (in Gross Motor Function Classification System
[GMFCS] levels I, II, III, IV, and V), subtypes of CP
(spastic, ataxic, and dyskinetic), and topographic distri-
bution of motor signs (hemiplegia, diplegia, and
quadriplegia).
Outcome measures
The primary outcome measure was changes in functioning
as measured by standardized outcome measures, namely
the GMFM49 and PEDI.50 Both the GMFM and PEDI
are considered sensitive instruments in detecting functional
change over time in children with CP.51,52 The intention
was to assess the effects of suit therapy on functioning
according to all ICF dimensions. However, all studies
included in our review focused on the activity dimension,
particularly in gross motor function. Only one study48 used
the PEDI, which assesses self-care, mobility, and social
function. This scale includes 197 skills from all the nine
domains of the activity and participation classification of
the International Classification of Functioning, Disability
and Health for Children and Youth (ICF-YC).
All studies included in this review41,45,47,48 have in com-
mon the use of the GMFM (66 or 88 items). Determining
the changes in motor function of CP children is of great
clinical relevance because it allows quantification of the
intervention results and standardization of information.
Three studies41,47,48 used the GMFM-66 and the remain-
ing study45 used GMFM-88.
Another widely used standardized classification system
reported in three studies41,47,48 is the GMFCS, which is
based on the concepts of abilities and limitations in gross
motor function. In these studies, the GMFCS was used to
classify the severity level of CP. It was not used as an out-
come measure because the GMFCS is not sensitive to
minor changes in motor function. Distinctions between the
different levels are based on functional capacities, the need
for assistive technology, and also on movement quality.53
The GMFM reflects aspects of the activity dimension of
the ICF and several studies have documented a very good
Table I: Continued
Study Selection criteria Sample
Variables/instru-
ments Intervention protocol Outcomes
Bailes
et al.48
Inclusion criteria: children
between 3 and 8y, able to
follow instructions, with a
diagnosis of CP, classified
in GMFCS Level III on the
GMFCS, with no evidence
of hip subluxation >35%
(migration index) and/or
scoliosis greater than 25
(Cobb angle) on hip and
spine X-rays, respectively,
within 6mo of the start of
intervention. Children
could not have previously
participated in an
intensive suit therapy
program. The parent/
guardian needed to speak
and read English, and
physician approval was
obtained.
Exclusion criteria:
intrathecal baclofen pump
therapy, history of
selective dorsal rhizotomy,
or Botox injections within
the past 3mo, orthopaedic
surgery within the past y,
serial casting within the
past mo, uncontrolled
seizures, and a diagnosis
of autism, attention-deficit
disorder.
20 children
randomly
assigned to:
TheraSuit
method (EG)
(n=10);
TheraSuit
method with
a ‘control
suit’ (CG)
(n=10).
Pediatric Evaluation
of Disability
Inventory (PEDI);
Gross Motor
Function Measure
(GMFM-66).
Both groups received the
therapy intervention for
4h daily, 5d/wk over a 3-
wk period (60h).
EG – TheraSuit method
wearing the TheraSuit
with elastic bungee cords
attached to the vest,
shorts, kneepads, and
shoes.
CG – TheraSuit method
wearing a ‘control suit’,
which consisted of only
the TheraSuit vest and
shorts, and did not have
the elastic bungee cords
attached.
Each child’s intervention
was individualized to the
goal of achieving the next
functional activity level. At
the end of the 3-wk
intervention, each child
was given an
individualized home
exercise program to
perform not more than 1h
daily from wks 4–9.
Between groups: no
significant differences.
Within-groups: GMFM-66
EG – Increase in scores
between baseline and 9th
wk (p=0.003);
CG – Increase in scores
between baseline and 9th
wk (p=0.036).
Within-groups: PEDI
EG – 4th wk vs baseline –
better in PEDI CA self-care
(p=0.042); 9th wk vs
baseline – better in PEDI
FS self-care (p=0.044),
PEDI CA self-care
(p=0.015) and PEDI FS
mobility (p=0.006); 9th wk
vs 4th wk – better in PEDI
FS mobility (p=0.032).
CG – No significant
differences.
CP, cerebral palsy; AST, Adeli suit therapy; NDT, neurodevelopmental treatment; GMFM, Gross Motor Function Measure; EG, experimental
group; CG, control group; GMFCS, Gross Motor Function Classification System; MAST, Modified Adeli suit therapy; CA, Caregiver Assis-
tance Scale; FS, Functional Skills Scale; PEDI, Pediatric Evaluation Disability Inventory.
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reliability, validity, and responsiveness of this measure.54,55
According to Ostensjo, Carlberg, and Vollestad,56 GMFM
measures activities classified in the mobility domain of the
ICF (d4), as well as a few neuromusculoskeletal and move-
ment-related body functions (ICF b7). Both versions of the
GMFM (66 or 88 items) were considered. GMFM is a
clinical tool designed to evaluate change in gross motor
function in children with CP across lifespan. The GMFM
is a quantitative, easy to administer instrument that assesses
gross motor functions based on the gross motor milestones
of typically developing children. This instrument is widely
used in clinical practice, especially by physical therapists.
By providing a detailed description of the child’s motor
function, it allows the therapist to define realistic goals and
to assess the efficacy of the intervention.49,57
Description of studies
Bar-Haim et al.47 compared AST with NDT in 24 chil-
dren with spastic CP (diplegia and quadriplegia) presenting
with severity (GMFCS levels II, III, or IV). Results
revealed significant improvements in GMFM scores after
1 month in the AST group and after 9 months in the
NDT group. Regarding the mechanical efficiency index,
there were improvements in the AST group after
10 months, particularly in children who had higher
GMFM-66 scores at baseline, but not in the NDT group.
However, when the retention of motor skills was tested
9 months after treatment there was no significant differ-
ence between the AST and NDT groups. Overall, this
study showed that intensive treatment with AST results in
significant improvements in gross motor function after
1 month of treatment (p=0.037). The decrease in gross
motor function at the follow-up (9mo after treatment) sug-
gests that patients receiving AST treatment may not retain
the skills they developed in the long term. On the other
hand, the NDT group only had significant improvements
in gross motor function at the follow-up. This suggests
that AST could result in short-term gains quickly,
although long-term improvements in gross motor function
may occur best with traditional NDT methods. The study
does not address if treatment in the AST at a lower fre-
quency (1–2 occasions/wk) would also result in improved
gross motor function (Table I).
Alagesan et al.45 compared the modified suit therapy,
which consisted of conventional therapy while wearing
Modified suit, with conventional therapy in 30 children
with a diagnosis of spastic CP diplegia. The severity level
of children with CP was not specified according to the
GMFCS. The results showed a statistically significant dif-
ference between groups (p=0.030), which indicated that
modified suit therapy was effective in improving the gross
motor function in children with spastic diplegia CP
(Table I).
Mahani et al.41 studied 36 children with a diagnosis of
spastic CP (diplegia and quadriplegia) and dystonic CP
(quadriplegia) with severity (GMFCS levels I, II, III, and
IV). There were three training groups: the Modified Adeli
suit therapy (MAST), the AST, and the NDT groups.
After 4 weeks of therapy the MAST group had signifi-
cantly higher GMFM scores than the other two groups
(both p≤0.001), whereas no significant difference was found
between the AST group and the NDT group (p=0.272).
These results were confirmed in the follow-up (16wks after
the treatment). At this stage, there were significant differ-
ences between the MAST and the AST groups (p≤0.001)
and between the MAST and NDT groups (p=0.001),
whereas no significant difference was found between the
AST and the NDT groups (p=0.379). This study showed
that MAST along with conventional physiotherapy is effec-
tive in improving the gross motor function in children with
spastic diplegia CP (Table I).
Bailes et al.48 addressed the effects of the TheraSuit
method compared with a control suit. A sample of 20 chil-
dren diagnosed with CP (no specified subtype) and classi-
fied in GMFCS Level III were assigned to two training
groups: the experimental group wore the TheraSuit with
elastic bungee cords attached to the vest, shorts, kneepads,
and shoes; and the control group wore a ‘control suit’
which consisted of only the vest and shorts of the Thera-
Suit and did not have the elastic bungee cords attached.
No statistical significant differences were found between
groups on the GMFM-66 or any domains of the PEDI,
either 4 or 9 weeks after treatment. Significant within-
group differences were found for the control group on the
GMFM-66 and for the experimental group on four of the
outcome measures: GMFM-66; PEDI Functional Skills
self-care scale; PEDI Caregiver Assistance self-care scale;
and PEDI Functional Skills mobility scale. This study does
not provide statistical evidence that the use of the Thera-
Suit is more effective than an intensive therapy program
wearing a control to improve motor function in children
with CP classified as GMFCS level III (Table I).
The participant characteristics (GMFM scores), and
number of sessions received during the treatment program
for each study are presented in Table II.
Level and quality of evidence
PEDro score for each study is listed in Table III. The
mean score of the four studies was 6.25 (interquartile range
5–8). One study45 reported a score of 5, two studies a
score of 6,41,47 and the remaining study obtained a score of
8,48 reflecting ‘fair’ to ‘good’ quality.36
As shown in Table III, all four studies specified the eligi-
bility criteria (indicator 1) which is a guarantee of the
external validity. Regarding the other criteria, all the stud-
ies41,45,47,48 ensured the random allocation of participants
(criterion 2), comparability of participant groups at base-
line (criterion 4), the assessors were blind to the evaluation
(criterion 7), the between-group statistical analysis was pre-
sented for at least one key outcome (criterion 10), and
point estimates of variability were provided for at least one
key outcome (criterion 11). Only the study by Alagesan
et al.45 did not reach more than 85% follow-up for at least
one key outcome (criterion 8). Only Bailes et al.48 met the
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PEDro criteria on concealed allocation and intention to
treat analysis (criteria 3 and 9). Finally, no study41,45,47,48
satisfied criteria 5 and 6 which relate to participants’ and
therapists’ blinding respectively.
Meta-analysis of intervention studies
Figure 2 presents the forest plots for the meta-analyses.
Gross motor functioning data was available for four studies
at post-treatment and three studies at follow-up. A signifi-
cant but small effect size was found at post-treatment
(g=0.46, 95% CI 0.10–0.82; z=2.51, p=0.01). The trial con-
ducted by Mahani et al.41 showed the largest effect size
(g=1.22), the trial by Alagesan et al.45 presented a marginal
effect (g=0.20), and the remaining trials47,48 presented non-
significant and trivial effects (g=0.03 and g=0.02 respec-
tively). We conducted sensitivity analyses by repeating the
primary analyses with the exclusion of the study by Alage-
san et al.45 which used a different version of the GMFM.
Excluding this study led to an increase in the magnitude of
treatment effects of 0.10. There was evidence of moderate
heterogeneity between trials (Q=8.38, p=0.04, I2=64%).
At follow-up, there was a similar overall effect (g=0.47,
95% CI 0.03–0.90). The trial by Bailes et al.48 presented a
trivial effect (g=0.15), the trial by Bar-Haim et al.47
reported a negative effect (g=0.43), and Mahani41
reported a significant large effect (g=1.33). There was evi-
dence of large heterogeneity between trials (Q=12.04,
p=0.002, I2=83%).
There was no indication of publication bias for any of
the assessment points.
DISCUSSION
The aim of this systematic review was to determine the
effect of suit therapy on functioning in children and ado-
lescents with CP.
The four studies (all RCTs) included presented ‘fair to
good’ quality evidence.37 The mean score in PEDro
scale37,58 was 6.25, ranging between 5 to 8, suggesting that
findings are credible. In this type of study it is not usually
possible to blind the therapist or the participants.59
On the basis of previous studies, it was hypothesized
that suit therapy would have a positive effect on gross
motor function in children and adolescents with CP. The
results of our research synthesis point to limited effects
of suit therapy in gross motor function of children and
adolescents with CP, presenting small combined effect
sizes (g=0.46 for post-treatment and g=0.47 for follow-
up), and considerable levels of heterogeneity between tri-
als.
This review presents methodological limitations which
advise caution when interpreting our results.
Methodological considerations
Some limitations can be mentioned, such as the restrictions
of language; only articles published in English, French,
Spanish, and Portuguese were reviewed, leading to poten-
tial bias on study selection – namely studies published in
Russian. The fact that we had no possibility of access to a
Russian translation might have compromised the inclusion
of relevant studies. Other limitations include the few eligi-
ble RCTs studies with good quality data, and the use of
meta-analytic techniques that present considerable advan-
tages for inference on treatment effects (as compared to
narrative analysis) but also present limitations and chal-
lenges. One must consider that the quality of a meta-analy-
sis derives from the quality of the studies included, and the
interpretation of results is to be conducted within a rigor-
Table II: Improvement in Gross Motor Function Measure score (%) after suit therapy (experimental group vs control group)
Studies
n GMFCS Baseline Post-treatment Follow-up
Hours of
treatment
(total)
EG CG EG CG EG CG EG CG EG CG EG CG
Bar-Haim et al.47 12 12 II, III, IV II, III, IV 54.4 52.2 55 52.9 54.7 54.1 40 40
Alagesan et al.45 15 15 – – 59.22 51.7 63.16 53.25 – – 30 30
Mahani et al.41 12 12 I, II, III, IV I, II, III, IV 42.92 42.92
41.41
59.59 51.01a
47.47b
62.62 49.49a
45.95b
40 40
Bailes et al.48 10 10 III III 47.93 51.34 49.1 52.61 50.08 54.37 60 60
aCG=Group 2. bCG=Group 3. GMFCS, Gross Motor Function Classification System; CG, control group; EG, experimental group.
Table III: Quality assessment of the four randomized controlled trials ac-
cording to the Physiotherapy Evidence Database scale
Study
Criteria of methodological rigour
1 2 3 4 5 6 7 8 9 10 11 Total
Bar-Haim et al.47 1 1 0 1 0 0 1 1 0 1 1 6
Alagesan et al.45 1 1 0 1 0 0 1 0 0 1 1 5
Mahani et al.41 1 1 0 1 0 0 1 1 0 1 1 6
Bailes et al.48 1 1 1 1 0 0 1 1 1 1 1 8
The Physiotherapy Evidence Database scale examines 11 aspects of
the quality of methodology including: (1) specification of eligibility
of participants; (2) randomization of participants; (3) allocation con-
cealment of participants; (4) comparability of participant groups at
baseline; (5) blinding of participants; (6) blinding of therapists; (7)
blinding of assessors; (8) more than 85% follow-up of participants
in at least one of key outcomes; (9) ‘intention-to-treat’ analysis; (10)
between-group statistical analysis of at least one of the key out-
comes; and (11) point estimate of at least one of the key outcomes.
According to the Physiotherapy Evidence Database guidelines, a
positive answer to each of the criteria 2 to 11 will yield 1 point,
obtaining a Physiotherapy Evidence Database score between 0 and
10.59
8 Developmental Medicine & Child Neurology 2015
ous methodological and theoretical framework which
allows a comprehensive analysis of the studies included.60
In the present review, the limited number of trials and
very small sample sizes in each trial (ranging from 10 to 15
participants, with a total of 110 participants) seriously limit
the conclusions that can be drawn from the effects of the
trials for each assessment point, as non-significant effects
may be because of low statistical power,46 and in the con-
text of a fixed-effect model, combined effects are largely
influenced by studies with larger samples. In addition, pub-
lication bias is a serious threat to the validity of meta-
analyses. Although inspection of publication bias did not
reveal significant asymmetry in the present review, this
may be because of low power in detecting real asymmetries
as a result of the limited number of studies.61
In addition, we also assumed that studies report data on
participants who received only the treatment offered in the
intervention condition, but we should consider the possi-
bility that participants could have gone through additional
forms of treatment, especially in studies that had long
intervals between pre- and post-interventions measure-
ment.
Another important limitation is the variability in patient
characteristics (GMFM scores) and number of sessions
received during the treatment program (Table II).
An additional consideration relates to the severity levels
of CP in GMFCS and the baseline score in GMFM-66/88
between studies. Only Bailes et al.48 included children with
similar functional level (GMFCS level III) in both (experi-
mental and control) conditions. Two studies included par-
ticipants with a large variation on severity levels from
GMFCS levels I to IV,41,47 and the study of Alagesan
et al.45 did not report on these levels (Table II). It is also
important to consider the relationship between age and
GMFCS level. A younger child with a GMFCS level I or
II usually has a better developmental prognosis than an
older child with a GMFCS level IV or V.62 According to
Rebel et al.,63 the estimations on gross motor prognosis in
children with CP require a prior assessment of GMFM.
Further, other variables must be considered, namely the
subtype of CP, the topographic distribution of the signs or
symptoms, the co-existence of other associated problems
(cognition, epilepsy, and status of sensory and perceptual
systems) and other contextual factors (economic and social
conditions, and the absence of treatment).
Finally, there are also concerns regarding the use of dif-
ferent versions of the GMFM (66 and 88 items) to assess
gross motor function. In this review, most studies41,47,48
used the GMFM-66 version. Although both versions evalu-
ate changes in gross motor function over time, the
GMFM-66 is a revised version of GMFM-88 in which
scores are converted and plotted in an interval scale of
gross motor function as opposed to the ordinal scaling of
the original GMFM-88. According to Wang and Yang,64
the responsiveness of the two versions of the GMFM for
children with CP was analyzed and the results showed ‘no
great difference in responsiveness between GMFM-66 and
GMFM-88 in discriminating between clinically meaningful
motor improvement and no improvement. However, under
this clinical condition, the correct negative responsiveness
(specificity) of GMFM-66 was better than that of
GMFM-88.’ Taking this remark into consideration, the
Study name Time point Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit Z-score p value Total
Alagesan et al. Post-treatment 0,200 –0,498 0,899 0,563 0,574 30
Bailes et al. Post-treatment 0,016 –0,824 0,855 0,036 0,971 20
Bar-Haim et al. Post-treatment 0,027 –0,746 0,800 0,069 0,945 24
Mahani et al. Post-treatment 1,219 0,588 1,849 3,789 0,000 48
0,463 0,101 0,824 2,510 0,012
–2,00 –1,00 0,00 1,00 2,00
Favours Control Favours Treatment
Post-treatment effects on gross motor function
Study name Time point Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit Z-score p value Total
Bar-Haim et al. Follow-up –0,434 –1,217 0,348 –1,088 0,277 24
Mahani et al. Follow-up 1,328 0,661 1,996 3,899 0,000 48
Bailes et al. Follow-up 0,148 –0,692 0,989 0,346 0,729 20
0,469 0,034 0,903 2,113 0,035
–2,00 –1,00 0,00 1,00 2,00
Favours Control Favours Treatment
Follow-up effects on gross motor function
Figure 2: Forest plots of the effects of the interventions on functioning at post-treatment and follow-up. CI, confidence interval.
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results of the trial by Alagesan et al.45 should be inter-
preted with caution, since the GMFM-88 version has a rel-
atively higher rate of false-positive findings which might
incorrectly report that a child undergoes motor improve-
ment when in fact that improvement was not clinically
meaningful.
PEDI is a useful measure that complements the GMFM
information by framing functioning in the context of daily
life activities. As only one study, Bailes et al.,48 used PEDI
as an additional measure, this could not be included in a
meta-analysis. Future studies should consider using both
measures as this knowledge is of great importance for
rehabilitation interventions, which often aim to improve a
person’s functioning in a controlled therapy setting with
the aim of also improving functioning in his/her natural
environment and daily routine. Considering this, the exam-
ination of the relations between capacity, capability, and
performance for other ICF-YC domains is of interest.
Agreement on standard instruments for use in research and
its testing is crucial for an adequate comparison of results
from trials across studies since, according to Kunz et al.,65
the large diversity of instruments is a major barrier to
meaningful comparisons across studies.
The use of valid and reliable instruments to measure
outcomes related to activities and social participation
should be encouraged in order to understand the impact of
this therapeutic intervention on children’s daily lives.
Therapy considerations
The content and intensity of therapy
Regarding the protocol description, three studies included
in this review45,47,48 did not fully specify the type of
activities and exercises performed by participants in the
experimental conditions who enrolled in different proto-
cols of suit therapy, and those in the control conditions
who enrolled in conventional treatment or NDT. It
would be helpful to have access to detailed descriptions
of the activities performed during therapy to know exactly
what was done in each condition. Only the study of
Mahani et al.41 reported sufficient detail on the exercises
applied during treatment sessions in the experimental
condition. According to Anttila et al.,8 providing detailed
protocol descriptions allows the identification of the
active components of treatment, promoting its replication
and correct transfer to other settings. Type of treatment
received during the intervention and follow-up periods
also varied between trials. Only the study by Bailes
et al.48 reported that participants did not receive any
other form of direct occupational therapy or physical
therapy during the study protocol to control for the
effects of co-interventions. The presence of potential co-
interventions (such as additional interventions and home
training of parents with their children) remained unclear
in most studies and might have influenced outcomes.
Even environmental factors such as parental support,
home, and leisure time activities may have an effect on
children’s functional abilities.
A further limitation concerns the duration of the proto-
col. Even though all studies used short intensive interven-
tions, their duration varied considerably, ranging from 2 to
4 hours per day over 3 to 4 weeks (Table II). There is no
consensus about the adequate duration of suit therapy pro-
grams. Liptak30 advocates that treatments can be adminis-
tered from 30 minutes to 2 hours a day, 5 to 6 days a
week for 4 weeks; Koscielny19 proposes 2 to 4 hours ses-
sions, 5 or 6 days a week, during 3 or 4 weeks; and Trahan
and Malouin66 advocated that an intermittent program of
four treatments per week lasting 4 weeks was well tolerated
when separated by rest periods. Motor function improve-
ments resulting from this program persisted through rest
periods. Results underline the need to reconsider the orga-
nization of physical rehabilitation programs in order to
find a routine that is adequate in terms of intensity, with-
out becoming tired, and also providing practice conditions
for consolidating the motor skills learned during the inten-
sive therapy.
The discussion on the benefits of intensive versus inter-
mittent programs is not new. In a previous study, Chris-
tiansen and Lange67 showed that intermittent or
continuous physiotherapy were both effective and did not
result in different GMFM-66 outcome measures between
two groups of children with CP. The results of a study by
Bower et al.68 showed that intensive physiotherapy, in con-
trast to a treatment approach based on collaborative goal-
setting, improved GMFM scores. However, this trend was
not statistically significant and declined in the follow-up
observation period. Ustad et al.69 highlight that recom-
mendations on the frequency of physical therapy for chil-
dren and adolescents with CP can be challenging since it is
important to consider age, medical problems, magnitude of
motor delay, as well as family conditions and support.
Another potential source of influence on treatment out-
comes is the therapist’s expertise and clinical reasoning.
Only Bailes et al.48 provided information on the expertise
level of the physical therapists involved. All other stud-
ies41,45,47 did not report on the previous experience and
skills of therapists. Jensen et al.70 reported that experienced
clinicians’ knowledge was more extensive in comparison to
novice clinicians and that they were more comfortable with
their knowledge level. Studies show that physical therapists
with higher self-awareness and confidence in their clinical
judgement, problem solving skills, and the ability to com-
municate this to each patient (i.e. tailoring) are more
responsive in their therapeutic interactions with patients,
can better handle environmental interruptions without dis-
rupting treatment, and are able to provide more frequent
and integrated cues and encouragement.
Finally, another concern relates to the difficulty in ade-
quately evaluating the efficacy of each suit therapy (AST,
MAST, or TheraSuit). Studies that use the same method-
ology but different patents would be necessary to under-
stand the differential effects of the suit. Only one study48
analyzed the different components of suit therapy and eval-
uated the effects of the suit itself.
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In conclusion, physical therapy for children with CP is
complex, because a large number of components may act
both independently and interdependently. It is influenced
by a diversity of factors, such as the type of therapy and its
intensity, the option for a standardized or individually tai-
lored approach, and skills and experience of the thera-
pists.71 Furthermore, additional unspecific stimuli may
affect the results and there might be differences between
therapists in how successful they are in motivating, engag-
ing, and advising children and parents. As multiple factors
are involved, specific ingredients responsible for effects are
frequently hard to discern.72 Research on potential moder-
ators of intervention effects is needed.
Recommendations for clinical practice
The effects of CP on gross motor function are variable. In
general, the relative deprivation of experience associated
with CP compromises the child’s overall development.
This condition mainly affects mobility and independence,
but it also influences other aspects of development and
learning (e.g. capacity to explore, to learn about space, and
to play). CP cannot be cured, but different therapeutic
interventions can improve the child’s functional abilities
and quality of life.73
Safer and more effective interventions have been devel-
oped for children with CP in the past decade as a conse-
quence of an exponential growth in high-quality CP
research. There are now at least 64 different therapeutic
interventions for CP. However, rapid expansion of evi-
dence-based interventions has made it difficult for health
professionals to keep up-to-date and for families to know
how to best help their child.12
According to Hurvitz et al.,74 families of children with
CP show a great interest in CAM treatments, with a
usage prevalence of 56%. The importance of innovative
and alternative therapies underlines the need to increase
the awareness and understanding of these treatment
modalities. The role of physical therapists in counselling
families is fundamental, because while families appear to
be better informed, they might not have the biomedical
information and expertise required to make a proper
evaluation of a treatment choice on their own.
Therefore, health care professionals need greater
education about CAM, before encouraging or discourag-
ing the families of CP children to use these approaches.
Ottolini et al.75 noted that most paediatricians consider
that their lack of knowledge interferes with their ability
to discuss CAM with patients. They emphasize a need
for greater education about CAM. Further studies are
needed to determine which factors make CAM modali-
ties desirable and effective, and to consider how these
factors can be incorporated into ‘standard care’ of chil-
dren with CP.
According to Sackett et al.,76 clinicians are expected to
integrate clinical experience with conscientious, explicit,
and judicious use of research evidence in order to make
informed decisions that maximize patients’ well-being. In
other words, clinicians are being told to embrace evidence-
based practice.
The findings of our meta-analysis suggest that further
studies are needed to examine the effects of suit therapy on
gross motor function in children and adolescents with CP.
Combining subjective and objective outcome measures
which assess all dimensions of ICF-YC is recommended to
guide treatment for children with CP and to weigh and
balance the benefits and harms of this CAM intervention.
Implications for future research
This systematic review and meta-analysis has highlighted
many methodological shortcomings in the studies
reviewed. Future RCTs should further analyze the content
of the therapy and consider the differential effects of its
intensity in relation to the outcomes achieved and the
actual effects of the suit alone.
Several questions are left unanswered and suggest the
need for future research before AST and suit therapy can
be accepted as an effective treatment. Considering the
results of this review, future studies should include: (1) a
detailed description of the intervention protocols specifying
the frequency, duration, and treatment plan; (2) samples
with appropriate sizes presenting power or sample size cal-
culations; (3) more homogeneous groups regarding age,
sex, type, and distribution of CP and GMFCS level; (4)
valid and reliable measures that assess all domains of ICF;
(5) longitudinal studies to assess the long-term impact of
suit therapy and that translate into improving function in a
person’s daily life in their normal environment; (6) data
that assess kinetic and kinematic parameters of postural
control; (7) control of parasite variables (e.g. level of expe-
rience of the physical therapists); (8) cost-effectiveness
analysis; and (9) assessment of the satisfaction of the
patient and family with the devices.
Considering the lack of clarity regarding the effects of
the elastic orthotic, leading to some speculation, it is nec-
essary to compare not only intensive suit therapy with
other physical therapy programs (conventional method or
NDT), but also to analyze specific immediate and long-
term effects of suit therapy on postural control using other
measures, namely kinematic and kinetic analyses and some
physiological markers, such as blood pressure, heart rate,
and metabolic rate.
CONCLUSION
Cerebral palsy is now the subject of much research and
evidence-based care recommended for this population is
continually and rapidly changing. Thus, it is important
that decision-making is guided by up-to-date evidence.
This systematic review and meta-analysis provides a state-
of-the-art synthesis of current evidence on the effects of
suit therapy on functioning in children and adolescents
with CP. The results showed that short intensive suit
therapy interventions have small effects on functioning at
post-treatment and follow-up, demanding some cautious
interpretation of the findings. Thus, physical therapists
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should take into consideration the lack of scientific evi-
dence regarding the effectiveness of suit therapy when
advising parents who are enquiring about this costly and
time-consuming treatment option.
In sum, the results of this systematic review and meta-
analysis do not support robust conclusions to prescribe or
suggest this new and ‘promising’ approach to therapy.
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